Abstract: The present invention relates generally to the field of tannate chemistry and more specifically to methods for processing tannate tablets, capsules, or other solid dosage forms. The present invention provides a novel manufacturing process for the conversion of one or more active pharmaceutical ingredients (“API”) into their tannate salt complexes while incorporating the complexes into a therapeutic solid-dosage form which also may include non-tannate API's. The first step of this process is to create a tannic acid powder blend by combining the salt or free base form of one or more APIs with tannic acid. After the dry blend is thoroughly mixed, a pharmaceutically acceptable liquid is added, for example by spraying, onto the dry powder blend facilitating the tannate salt conversion process. The conversion product is then added to additional dry powders thereby reducing the overall liquid content to a level that is more typical of wet granulation processes.